CAPE TOWN, South Africa — The 13-valent pneumococcal conjugate vaccine (PCV-13) offers moderate protection against the most common forms of pneumococcal community-acquired pneumonia in healthy elderly people, a large prospective trial shows.
"Pneumococcal conjugate vaccines are effective in preventing invasive pneumococcal disease and pneumonia in children, but vaccine efficacy has not been investigated in adults older than 65," said Marc Bonten, MD, professor of molecular epidemiology of infectious disease at the Julius Center for Health Sciences and Primary Care in Utrecht, the Netherlands.
"A clear medical need exists among adults to prevent pneumococcal disease, including pneumococcal community-acquired pneumonia. Whether the benefit we demonstrated in individuals translates into an overall public health benefit needs further analyses," he said.
The study results were presented here at the 16th International Congress on Infectious Diseases.
READ MORE from medscape.com
No comments:
Post a Comment